Drugs & TargetsFree European Commission approves Venclyxto in CLL indication March 13, 2020Vol.46 No.11
Clinical RoundupFree FDA encourages inclusion of older adult patients in cancer clinical trials March 13, 2020Vol.46 No.11
Clinical RoundupFree Phase III GY004 for Cediranib and Lynparza doesn’t meet PFS endpoint in ovarian cancer indication March 13, 2020Vol.46 No.11
Clinical RoundupFree Copper IUDs less likely to contribute to cervical cancer than hormonal IUDs March 13, 2020Vol.46 No.11
COVID-19 & CancerFreeTrials & Tribulations A conversation about COVID-19: reflecting on first cases in Kansas March 13, 2020Vol.46 No.11By Roy A. Jensen
Conversation with The Cancer LetterCOVID-19 & CancerFree Is your cancer center ready for COVID-19? March 13, 2020Vol.46 No.11By Alexandria Carolan
COVID-19 & CancerFree Pandemic: Bracing for coronavirus surge March 13, 2020Vol.46 No.11By Alexandria Carolan and Matthew Bin Han Ong
COVID-19 & CancerFreeGuest Editorial COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk March 13, 2020Vol.46 No.11By Karen E. Knudsen and Roy A. Jensen
Conversation with The Cancer LetterCOVID-19 & CancerFree What to expect: Oncology’s response to coronavirus in Italy"It's like being in a war" March 11, 2020Vol.46 No.11By Alexandria Carolan
COVID-19 & CancerFree Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain March 04, 2020Vol.46 No.10By Alexandria Carolan
